135 related articles for article (PubMed ID: 10963376)
41. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
42. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
44. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
45. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
46. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver.
Tannapfel A; Weinans L; Geissler F; Schütz A; Katalinic A; Köckerling F; Hauss J; Wittekind C
Dig Dis Sci; 2000 Feb; 45(2):317-24. PubMed ID: 10711445
[TBL] [Abstract][Full Text] [Related]
47. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
[TBL] [Abstract][Full Text] [Related]
48. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
[TBL] [Abstract][Full Text] [Related]
49. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a marker that predicts presence of invasion in papillary biliary tumors.
Sasaki M; Sato Y
Hum Pathol; 2017 Apr; 62():152-159. PubMed ID: 28089541
[TBL] [Abstract][Full Text] [Related]
50. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.
Boberg KM; Schrumpf E; Bergquist A; Broomé U; Pares A; Remotti H; Schjölberg A; Spurkland A; Clausen OP
J Hepatol; 2000 Mar; 32(3):374-80. PubMed ID: 10735605
[TBL] [Abstract][Full Text] [Related]
51. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
52. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
53. A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model.
Iguchi T; Yamashita N; Aishima S; Kuroda Y; Terashi T; Sugimachi K; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
Oncology; 2009; 76(4):293-300. PubMed ID: 19262069
[TBL] [Abstract][Full Text] [Related]
54. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719
[TBL] [Abstract][Full Text] [Related]
55. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
56. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S
Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
[TBL] [Abstract][Full Text] [Related]
57. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
58. Mutational landscape of intrahepatic cholangiocarcinoma.
Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
[TBL] [Abstract][Full Text] [Related]
59. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
Foulkes WD; Stamp GW; Afzal S; Lalani N; McFarlane CP; Trowsdale J; Campbell IG
Br J Cancer; 1995 Oct; 72(4):883-8. PubMed ID: 7547235
[TBL] [Abstract][Full Text] [Related]
60. Effect of Mir-122 on Human Cholangiocarcinoma Proliferation, Invasion, and Apoptosis Through P53 Expression.
Wu C; Zhang J; Cao X; Yang Q; Xia D
Med Sci Monit; 2016 Jul; 22():2685-90. PubMed ID: 27472451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
